Pro Medicus Limited reported solid underlying operating performance in FY26, with revenue reaching A$261.7 million, up 22.9 percent from A$213.0 million in the prior year. More significantly, underlying profit before tax grew 24.2 percent to A$205.2 million from A$165.2 million, demonstrating that the company’s core business expansion is outpacing revenue growth through improved operational leverage. This metric, which excludes currency movements and fair value adjustments to financial assets, provides the clearest view of PME’s underlying earning power.
The reported profit figure of A$377.5 million appears dramatically higher at first glance, representing a 131.2 percent increase from A$163.3 million in FY25, but this is largely attributable to a A$174.2 million fair value gain on other financial assets rather than operational performance. Currency losses of A$1.9 million provided a minor headwind. While the fair value movement is a genuine component of shareholder wealth creation, investors should recognize that the underlying business delivered more modest but still healthy growth. The company has noted that it revised its definition of underlying profit to include interest income, which improved the FY25 restated figure from A$157.7 million to A$165.2 million, making the year-on-year comparison more consistent.
PME’s capital management and dividend policy reflect confidence in the business trajectory. The final dividend of 37.0 cents per share, up from 30.0 cents, combines with the interim dividend of 32.0 cents paid in March 2026, up from 25.0 cents, to deliver total ordinary dividends of 69.0 cents for the year compared to 55.0 cents in FY25. All dividends are fully franked, providing favorable tax treatment for Australian investors. The after-tax profit of A$265.3 million increased 130.3 percent, though again this incorporates the fair value gains. Net tangible assets per share nearly doubled to A$4.10 from A$2.26, indicating the company is building a stronger balance sheet alongside its operational growth.
For investors tracking PME, the key takeaway is that underlying business momentum remains solid with revenue and core profit growing at around 23 to 24 percent, suggesting the company continues to expand its addressable markets and execution capability. The fair value movements represent opportunistic gains rather than recurring operating benefits, so projecting earnings should anchor to the underlying profit figure. Investors should monitor whether this level of organic growth can be sustained, the trajectory of those financial assets driving the fair value movements, and whether dividend growth continues to be supported by operating cash generation. The announcement is flagged as price sensitive and deemed material by the ASX.
View the full ASX announcement (PDF)
About Pro Medicus Limited (ASX: PME)
Pro Medicus Limited is an Australian health imaging software company headquartered in Victoria that develops advanced diagnostic imaging solutions for the global healthcare market. The company’s main business segment centers on its Visage imaging platform, a viewer and analysis solution used by hospitals and medical institutions to manage and interpret medical images. Pro Medicus operates primarily through its U.S. subsidiary Visage Imaging, Inc., serving major healthcare systems across North America and internationally on a transaction-based licensing model.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
